(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025
Ocular Therapeutix, Inc. has suddenly moved from sleepy mid-cap biotech to front-page ticker.
Oculis Stock Shock: Eye-Drop Trial Miss Sends Shares Sliding
Oculis Holding AG shares fell sharply on Friday after the Swiss eye-drug developer said two late-stage trials of its OCS-01 eye drops failed to meet their main goal in diabetic macular edema, a diabetes-linked swelling in the retina that can damage sight. The company said it does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug in that indication.
Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges
As of the close on Friday, December 5, 2025, Ocular Therapeutix, Inc. finished regular trading at $12.58 per share, up about 1.2% on the day, with after‑hours quotes on some platforms briefly touching the $14 area. StockAnalysis+1
TechStock² Updates
